infliximab
Subcutaneous Infliximab Found Effective With or Without an Immunosuppressant
Patients who achieved a clinical response to subcutaneous infliximab showed no meaningful differences in outcomes ...
APRIL 30, 2025
Overcoming Biosimilar Utilization Barriers
The successful implementation of an infliximab biosimilar at Boston Medical Center was one of several lessons for ...
APRIL 11, 2025
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 27, 2024
FDA Approves Zymfentra for IBD
The FDA approved Zymfentra for the treatment of inflammatory bowel disease.
OCTOBER 27, 2023
Treatments for Immunotherapy-Induced Colitis Might Affect Cancer Outcomes
Biologic agents commonly used to treat gastrointestinal problems associated with the use of immune checkpoint ...
NOVEMBER 12, 2021
Deep Remission Not Necessarily Linked To Better Outcomes in Crohn’s
Patients with Crohn’s disease who achieve deep remission one year after combination therapy with infliximab ...
MARCH 19, 2021
SubQ Infliximab Holds Up Against IV Form for IBD
Patients with inflammatory bowel disease are one step closer to having a subcutaneous version of infliximab.
SEPTEMBER 11, 2020
Feds to Push for More Biosimilar Competition
The FDA and the FTC announced they will take further action to stem anticompetitive practices that are blocking ...
FEBRUARY 17, 2020
Ixifi, a Biosimilar for RA, Receives Approval
FDA approves another biosimilar for Remicade. Ixifi has all of the same indications.
DECEMBER 15, 2017
FDA Approves Second Biosimilar of Remicade
Renlexis, a TNF blocker, will be indicated for the treatment of adult and pediatric Crohn’s disease, adult ...
APRIL 24, 2017
Biosimilar Infliximab Takes Cautious Steps Into Market
Stakeholders assess lessons learned from Pfizer’s year-end 2016 “soft launch” of infliximab-dyyb ...
JANUARY 23, 2017
Despite Second Biosimilar Approval, ‘Hamlet Moments’ Still Loom at FDA
What’s more important—pharmacokinetics or price—when it comes to adoption of biosimilars in the ...
APRIL 6, 2016
